AtriCure Inc (ATRC)

Currency in USD
55.39
+1.28(+2.37%)
Closed·
55.390.00(0.00%)
·
ATRC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
54.0356.19
52 wk Range
25.3666.02
Key Statistics
Prev. Close
54.11
Open
54.03
Day's Range
54.03-56.19
52 wk Range
25.36-66.02
Volume
813.13K
Average Volume (3m)
1.03M
1-Year Change
53.138%
Book Value / Share
10.48
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATRC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
64.89
Upside
+17.15%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings downwards for the upcoming period

AtriCure Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Analyst Ratings

7 Buy
3 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 64.89
(+17.15% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy70.00+26.38%-MaintainNov 12, 2026
JPMorgan
Hold62.00+11.93%36.00MaintainNov 04, 2026
Needham
Buy70.00+26.38%64.00MaintainNov 04, 2026
Stifel
Buy70.00+26.38%65.00MaintainNov 04, 2026
Piper Sandler
Buy70.00+26.38%60.00MaintainNov 04, 2026

AtriCure Inc Earnings Call Summary for Q3/2026

  • AtriCure reported Q3 2026 EPS of $0.17, beating consensus loss estimate of $0.04, with revenue of $154.45M topping forecasts by $3.3M.
  • U.S. revenue surged 17.1% to $128M, driving overall 15% growth; gross margin improved 180 bps to 77.3% year-over-year.
  • Company raised FY 2026 revenue guidance to $606M-$610M, implying 13.4%-14.1% growth; adjusted EBITDA outlook increased to $91M-$94M.
  • Shares fell 2% after-hours to $59.20 despite beat, as investors took profits near 52-week highs and digested Q4 margin pressure warnings.
  • Management expects BoxX-NoAF trial enrollment completion by year-end with spring 2027 data readout; new 30mm AtriClip FLEX-Mini launches December 2026.
Last Updated: 2026-11-03, 05:24 p/m
Read Full Transcript

Earnings

Latest Release
Nov 03, 2026
EPS / Forecast
0.17 / -0.04
Revenue / Forecast
154.45M / 151.15M
EPS Revisions
Last 90 days

ATRC Income Statement

Compare ATRC to Peers and Sector

Metrics to compare
ATRC
Peers
Sector
Relationship
P/E Ratio
189.5x−0.3x−0.2x
PEG Ratio
1.260.120.00
Price/Book
5.3x2.0x2.6x
Price / LTM Sales
4.8x1.8x2.6x
Upside (Analyst Target)
17.1%68.9%76.9%
Fair Value Upside
Unlock11.8%14.9%Unlock

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
30.97M60.81%1.72B
Other Institutional Investors
23.63M39.19%1.31B
Public Companies & Retail Investors
0.000.00%0.00
Total
54.6M100.00%3.02B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.15.60%7,943,332439,981
Wellington Management Group LLP8.08%4,116,204227,997

People Also Watch

32.360
HRTG
-0.15%
95.44
FELE
-2.75%
640.53
CVCO
-1.46%
26.29
HSTM
+0.19%

FAQ

What Is the AtriCure (ATRC) Stock Price Today?

The AtriCure stock price today is 55.39 USD.

What Stock Exchange Does AtriCure Trade On?

AtriCure is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for AtriCure?

The stock symbol for AtriCure is "ATRC."

What Is the AtriCure Market Cap?

As of today, AtriCure market cap is 2.76B USD.

What Is AtriCure's Earnings Per Share (TTM)?

The AtriCure EPS (TTM) is 0.31.

When Is the Next AtriCure Earnings Date?

AtriCure will release its next earnings report on Feb 23, 2027.

From a Technical Analysis Perspective, Is ATRC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has AtriCure Stock Split?

AtriCure has split 0 times.

How Many Employees Does AtriCure Have?

AtriCure has 1350 employees.

What is the current trading status of AtriCure (ATRC)?

As of Nov 21, 2026, AtriCure (ATRC) is trading at a price of 55.39 USD, with a previous close of 54.11 USD. The stock has fluctuated within a day range of 54.03 USD to 56.19 USD, while its 52-week range spans from 25.36 USD to 66.02 USD.

What Is AtriCure (ATRC) Price Target According to Analysts?

The average 12-month price target for AtriCure is 64.89 USD, with a high estimate of 70 USD and a low estimate of 50 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +17.15% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.